Evidence map›Paper›PMID 30762724›Full record

SynthesisMedicine2019

Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies: A meta-analysis.

Yibo Yang, Jing Wang, Hui Li, Lihong Liu, Maojin Yao, Tao Xiao

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Genome-wide Analysis IdentifiedIntegrative cancer therapies
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yibo YangDepartment of Sport Surgery and Sport Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University).
Jing WangDepartment of Sport Surgery and Sport Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University).
Hui LiDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Lihong LiuDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Maojin YaoDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA.
Tao XiaoDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Hunan Normal University · CNUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSEMA4D and its high affinity receptor Plexin-B1 showed a promising prognosis prediction for carcinoma patients in recent studies, we performed a meta-analysis to evaluate the prognostic role of them in various malignancies.

methodsA systematic literature search was performed in PubMed, Embase, Web of Science, and CNKI from inception till July 2017. Eligible studies were identified by different reviewers. Hazard ratios (HRs)/related ratios (RRs) and their corresponding 95% confidence intervals (CIs) were extracted to investigate the relevance between malignancies prognosis and SEMA4D/Plexin-B1.

resultsAround 2638 patients from 14 studies were included in this meta-analysis. High expression of SEMA4D was significantly associated with overall survival (OS) and disease-free survival/progression-free survival/recurrence-free survival (DFS/PFS/RFS) in tumors (respectively, HRos = 2.05, 95%CI: 1.68-2.50, P < .001; HRdfs/pfs/rfs = 1.59, 95%CI = 1.27-1.98, P < .001). However, the relationship between SEMA4D expression and prognosis of breast cancer patients was failed to find (HR = 0.76, 95%CI = 0.32-1.82, P = .539). Plexin-B1 level showed a significant positive correlation both with OS and DFS of Caucasian breast cancer patients (respectively, HRos = 0.56, 95%CI: 0.39-0.79, P = .001; HRdfs = 0.68, 95%CI = 0.51-0.90, P = .008)

conclusions: SEMA4D could be a prospective biomarker for prognostic prediction of various malignancies except breast cancer. For Caucasian breast cancer patients, SEMA4D's high affinity receptor Plexin-B1 showed a significant positive correlation with survival.

Indexed as

Antigens, CDBiomarkers, TumorBreast NeoplasmsDisease-Free SurvivalHumansNeoplasmsNerve Tissue ProteinsPrognosisProportional Hazards ModelsProspective StudiesReceptors, Cell SurfaceSemaphorinsAntigens, CDBiomarkers, TumorCD100 antigenNerve Tissue ProteinsPLXNB1 protein, humanReceptors, Cell SurfaceSemaphorins

Identifiers

PMID30762724
PMCPMC6407964
OpenAlexW2911823157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.